Founded in 2018, Hellenic Dynamics is a licensed cultivator and supplier of finished pharmaceutical standard medical cannabis products operating from a dedicated 195,506 square meter facility set in the rolling hills of Northern Greece. Hellenic Dynamics is specifically involved in the cultivation, production and export of tetrahydrocannabinol (“THC”) dominant strains of dried medical cannabis flowers and flower extracts to the growing medical cannabis markets across Europe, worth €4.09bn in 2019 and expected to reach €43.3bn by 2027, growing at a CAGR of 29.6% during this period.
Focused on the cultivation
and supply of THC dominant medical cannabis products, from plant to patient.
About us 
Medical cannabis, especially in higher THC doses, has been approved for use in the United Kingdom and Germany plus 24 other European countries for conditions including but not limited to chronic pain, Spinal cord treatment, Anxiety, HIV/AIDS Appitite loss, Multiple Sclerosis, Crohn’s disease, PTSD, Chemotherapy side effects, Glaucoma, Anorexia, Lennox-Gastaut syndrome, Alzheimer’s, Dravet syndrome, Tourette’s syndrome, Intractable spasticity and Cachexia.
Hellenic was awarded its licence from the Greek government in 2019 for a total of 40,000 square meters of active cultivation area within our facility, with no limitations on the THC content of the cultivars grown, the overall volume of production or total export quantities of flowers per annum. This is one of the largest licences of its kind issued in Europe due to the size and scale of the facility and the high regulatory standards under which Hellenic Dynamics operates.
Hellenic Dynamics has an experienced management team with significant medial cannabis cultivation and business development experience. This skillset is underpinned by a number of high profile partnerships and collaboration agreements that cover all aspects of the Company’s marketing, sales, security and existing legislative and legal frameworks both domestically and for target European sales territories.
Prime position to capitalize on the European medical cannabis market estimated to be worth €37 bn by 2027.
Team has extensive medical cannabis cultivation experience at scale along with public markets background.
Intention to build a proprietary IP protected library of THC dominant genetics.
Partnership with the American Farm School, Southern Europe’s preeminent agricultural institution.
25 countries in Europe now allow the supply of THC Medical Cannabis via prescription.
Integrated model spans cultivation, production, and distribution.
One of the lowest power, utility and skilled labor costs in Europe with easy distribution to all target markets.
Off take agreements in place for THC dominant products into first target market Germany.